1 hour ago
Phase 2b data from the 16-week extension of REZOLVE-AA suggest rezpegaldesleukin leads to continued hair regrowth through 52 weeks.
1 hour ago
This interview highlights positive 12-month phase 3 results on clascoterone 5% topical solution for mild-to-moderate androgenetic alopecia, or hair loss.
1 hour ago
Phase 3 MIRANDA found tozorakimab reduced COPD exacerbations in former smokers despite inhaled maintenance therapy.
2 hours ago
Etavopivat reduced VOC events by 27% and improved hemoglobin response in the phase 3 HIBISCUS trial in sickle cell disease.
3 hours ago
In the final episode, "Integrating Comparative Evidence to Optimize Psoriasis Treatment Decisions," the panelists explore how the full body of available evidence, including comparative analyses, long term extension studies, real world data, and clinical experience, can be integrated into practical treatment decision making for plaque psoriasis.